1-20 of 21
Pascale André
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

Olivier Demaria, Guillaume Habif, François Le Floch, Laura Chiossone, Romain Remark, Marie Vetizou, Nadia Maurel, Laurent Gauthier, Yannis Morel, Carine Paturel, Eric Vivier, Pascale Andre
Journal: Blood
Blood (2022) 140 (Supplement 1): 11559.
https://doi.org/10.1182/blood-2022-163561
Published: 2022
Journal Articles

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Norbert Vey, Pierre-Yves Dumas, MD, Christian Recher, MD PhD, Lauris Gastaud, MD, Bruno Lioure, MD, Claude-Eric Bulabois, MD, Cecile Pautas, Jean-Pierre Marolleau, MD PhD, Stéphane Leprêtre, MD, Emmanuel Raffoux, MD, Xavier Thomas, MD, Yosr Hicheri, Caroline Bonmati, MD, Bruno Quesnel, MD PhD, Philippe Rousselot, Sylvie Castaigne, MD PhD, Eric Jourdan, MD, Jean Valère Malfuson, Gaelle Guillerm, MD, Jean Henri Bouhris, Mario Ojeda, MD, Mathilde Hunault, MD PhD, Norbert Ifrah, MD PhD, Claude Gardin, MD PhD, Andre Delannoy, MD, Lucile Beautier, Carine Paturel, PhD, Pascale Andre, PhD, Robert Zerbib, Claude Preudhomme, PharmD, PhD, Antoine Toubert, MD PhD, Nicolas Dulphy, PhD, Daniel Olive, MD PhD, Arnaud Pigneux, MD, Herve Dombret, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 889.
https://doi.org/10.1182/blood.V130.Suppl_1.889.889
Published: 2017
Journal Articles

Lirilumab Enhances Anti-Tumor Efficacy of Elotuzumab

Caroline Sola, PhD, Mathieu Blery, PhD, Cécile Bonnafous, PhD, Elodie Bonnet, Nicolas Fuseri, Robert F Graziano, PhD, Yannis Morel, PhD, Pascale André, PhD
Journal: Blood
Blood (2014) 124 (21): 4711.
https://doi.org/10.1182/blood.V124.21.4711.4711
Published: 2014
Journal Articles

Effects of IL-21, KIR Blockade, and CD137 Agonism on the Non-Clinical Activity of Elotuzumab

Michael Robbins, BS, Maria Jure-Kunkel, DVM, PhD, Gennaro Dito, BS, Pascale Andre, PhD, Hui-fen Zhang, PhD, Natalie Bezman, PhD, Robert F Graziano, PhD
Journal: Blood
Blood (2014) 124 (21): 4717.
https://doi.org/10.1182/blood.V124.21.4717.4717
Published: 2014
Journal Articles

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Holbrook E. Kohrt, Ariane Thielens, Aurelien Marabelle, Idit Sagiv-Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, Eric Vivier, François Romagné, Ronald Levy, Mathieu Bléry, Pascale André
Journal: Blood
Blood (2014) 123 (5): 678–686.
https://doi.org/10.1182/blood-2013-08-519199
Published: 2014
Includes: Supplemental data
Journal Articles

Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies

Holbrook E Kohrt, MD, PhD, Ariane Thielens, Aurelien Marabelle, MD, MSc, Idit Sagiv Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra K Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, PhD, Eric Vivier, PhD, Francois Romagne, PhD, Ronald Levy, MD, Pascale Andre, PhD, Mathieu Blery, PhD
Journal: Blood
Blood (2013) 122 (21): 4417.
https://doi.org/10.1182/blood.V122.21.4417.4417
Published: 2013
Journal Articles

Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia

Norbert Vey, MD, Jean-Henri Bourhis, MD, PhD, Christian Recher, MD PhD, Anne Etienne, MD, Aude Charbonnier, MD, PhD, Pascale Andre, PhD, Jérôme Rey, MD, Franceline Calmels, Robert Zerbib, Renaud Buffet, MD, Thomas Prebet, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2696.
https://doi.org/10.1182/blood.V122.21.2696.2696
Published: 2013
Journal Articles

A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma

Don M. Benson, Jr., MD, PhD, Adam D Cohen, MD, Craig C Hofmeister, MD, Munshi C Nikhil, MD, Sundar Jagannath, MD, Yvonne A Efebera, MD, Gary Spitzer, MD, Robert Zerbib, Pascale Andre, PhD, Shawna Oxier, Michael A. Caligiuri, MD
Journal: Blood
Blood (2013) 122 (21): 3181.
https://doi.org/10.1182/blood.V122.21.3181.3181
Published: 2013
Journal Articles

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

Clinical Trials & Observations
Norbert Vey, Jean-Henri Bourhis, Nicolas Boissel, Dominique Bordessoule, Thomas Prebet, Aude Charbonnier, Anne Etienne, Pascale Andre, François Romagne, Don Benson, Herve Dombret, Daniel Olive
Journal: Blood
Blood (2012) 120 (22): 4317–4323.
https://doi.org/10.1182/blood-2012-06-437558
Published: 2012
Includes: Supplemental data
Journal Articles

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Don M. Benson, Jr, Craig C. Hofmeister, Swaminathan Padmanabhan, Attaya Suvannasankha, Sundar Jagannath, Rafat Abonour, Courtney Bakan, Pascale Andre, Yvonne Efebera, Jérôme Tiollier, Michael A. Caligiuri, Sherif S. Farag
Journal: Blood
Blood (2012) 120 (22): 4324–4333.
https://doi.org/10.1182/blood-2012-06-438028
Published: 2012
Journal Articles

A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results

Don M. Benson, Jr., MD, PhD, Adam D Cohen, MD, Nikhil C. Munshi, MD, Sundar Jagannath, MD, Gary Spitzer, MD, Craig C. Hofmeister, MD, Robert Zerbib, Pascale Andre, PhD, Yvonne A Efebera, M.D., Shawna Oxier, Michael A. Caligiuri, M.D.
Journal: Blood
Blood (2012) 120 (21): 4058.
https://doi.org/10.1182/blood.V120.21.4058.4058
Published: 2012
Journal Articles

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Brief Report
Don M. Benson, Jr, Courtney E. Bakan, Shuhong Zhang, Shauna M. Collins, Jing Liang, Shivani Srivastava, Craig C. Hofmeister, Yvonne Efebera, Pascale Andre, Francois Romagne, Mathieu Bléry, Cécile Bonnafous, Jianying Zhang, David Clever, Michael A. Caligiuri, Sherif S. Farag
Journal: Blood
Blood (2011) 118 (24): 6387–6391.
https://doi.org/10.1182/blood-2011-06-360255
Published: 2011
Includes: Supplemental data
Journal Articles

Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML)

Jerome Rey, MD, Nicolas Anfossi, PhD, Pascale Andre, PhD, Jean-Marie Boher, Florence Orlanducci, Violette Breso, Valentine Perri, Thomas Prebet, MD, PhD, Aude Charbonnier, MD, PhD, Eloïse Perrot, Francois Romagne, PhD, Norbert Vey, MD, Daniel Olive, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2189.
https://doi.org/10.1182/blood.V118.21.2189.2189
Published: 2011
Journal Articles

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Inger S. Nijhof, MD, Michel de Weers, PhD, Pascale Andre, PhD, Berris van Kessel, Henk M. Lokhorst, MD, Paul W.H.I. Parren, PhD, Yannis Morel, PhD, Tuna Mutis, MD PhD
Journal: Blood
Blood (2011) 118 (21): 1865.
https://doi.org/10.1182/blood.V118.21.1865.1865
Published: 2011
Journal Articles

Long Lasting Alteration of Natural Killer Cells Post-Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML).

Daniel Olive, MD, PhD, Nicolas Anfossi, Pascale Andre, PhD, Jerome Rey, Florence Orlanducci, Violette Breso, Valentine Peri, Thomas Prébet, MD, Aude Charbonnier, MD, PhD, Eloise Perrot, Francois Romagne, PhD, Norbert Vey
Journal: Blood
Blood (2009) 114 (22): 1653.
https://doi.org/10.1182/blood.V114.22.1653.1653
Published: 2009
Journal Articles

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.

Don Benson, MD, PhD, Courtney E Bakan, Lana Alghothani, Craig C. Hofmeister, MD, Yvonne A Efebera, M.D., Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Steven M Devine, MD
Journal: Blood
Blood (2009) 114 (22): 4641.
https://doi.org/10.1182/blood.V114.22.4641.4641
Published: 2009
Journal Articles

A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH2101) in Elderly Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological Effects of a Single Dose Followed by Repeated Dosing.

Norbert Vey, Jean-Henri Bourhis, MD, PhD, Herve Dombret, MD, PhD, Dominique Bordessoule, Thomas Prébet, MD, Aude Charbonnier, Stephane de Botton, Nicolas Boissel, MD, PhD, Christine d'Arnoux, MD, Francois Romagne, PhD, Pascale Andre, PhD, Jerome Tiollier, Patrick Squiban, Didier Blaise, Daniel Olive, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 632.
https://doi.org/10.1182/blood.V114.22.632.632
Published: 2009
Journal Articles

Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.

Don Benson, MD, PhD, Craig C. Hofmeister, MD, Swaminathan Padmanabhan, MD, MBBS, Rafat Abonour, Attaya Suvannasankha, MD, Alain Mita, Patrick Squiban, MD, Megan K Smith, MS, CNP, RN, Courtney E Bakan, Marc Marzetto, Pascale Andre, PhD, Jerome Tollier, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD
Journal: Blood
Blood (2009) 114 (22): 2880.
https://doi.org/10.1182/blood.V114.22.2880.2880
Published: 2009
Journal Articles

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Don Benson, MD, PhD, Courtney E Bakan, Shuhong Zhang, PhD, Lana Alghothani, Jing Liang, Craig Hofmeister, MD, Shivani Srivastava, MD, Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, MD, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD
Journal: Blood
Blood (2009) 114 (22): 3870.
https://doi.org/10.1182/blood.V114.22.3870.3870
Published: 2009
Journal Articles

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Francois Romagné, Pascale André, Pieter Spee, Stefan Zahn, Nicolas Anfossi, Laurent Gauthier, Marusca Capanni, Loredana Ruggeri, Don M. Benson, Jr, Bradley W. Blaser, Mariella Della Chiesa, Alessandro Moretta, Eric Vivier, Michael A. Caligiuri, Andrea Velardi, Nicolai Wagtmann
Journal: Blood
Blood (2009) 114 (13): 2667–2677.
https://doi.org/10.1182/blood-2009-02-206532
Published: 2009
Includes: Supplemental data